Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chemically induced intracellular hyperthermia

a hyperthermia and chemical technology, applied in the field of therapeutic pharmacological agents, can solve the problems of reducing the effect of heat loss, loosening, and reducing the amount of sulphur dioxide in the sulphur dioxide layer, and achieve the effects of enhancing intracellular heat and free radicals, enhancing energy metabolism and heat production, and enhancing safety and effectiveness

Inactive Publication Date: 2010-03-04
TEXAS PHARMA
View PDF18 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This approach enables more effective and targeted treatment of various diseases by achieving higher intracellular temperatures and increased oxygen free radical production, enhancing the therapeutic effect while reducing toxicity and improving temperature control compared to external heating methods.

Problems solved by technology

Likewise, unstable atherosclerotic plaques are presumed to rupture because they have a dense infiltration of macrophages which have high metabolic rates and generate excessive enzymes and heat, causing the plaque to degrade and loosen.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chemically induced intracellular hyperthermia
  • Chemically induced intracellular hyperthermia
  • Chemically induced intracellular hyperthermia

Examples

Experimental program
Comparison scheme
Effect test

example 1

Method of Using DNP with Glucagon to Treat Parasitic Infections, Hydatid Disease of the Liver

[0117]History: A 52 year old white Swiss male, European fox hunting dog trainer, presented with right upper quadrant pain and vomiting. Past history revealed he had hepatic“cyst” surgery 2 years ago. Preoperatively, he was treated with albendazole. Only one dose of albendozale was given because of a “near death” anaphylactic reaction. He denied history of weight loss, pulmonary, cardiac, neurologic or thermoregulatory problems. There was no history of alcohol abuse or medication use. The patient was adamantly opposed to any further surgery or treatment with albendazole or mebendazole.

[0118]Physical Examination: Weight=90 Kg; height=177.8 cm; BP=140 / 80; HR=76 & reg; Resp.=18 min; T=37.0

[0119]An old well healed scar consistent with prior hepatic surgery was present. Physical exam otherwise was unremarkable.

[0120]Laboratory studies: EKG, chest X-ray, blood panel, including serum electrolytes, t...

example 2

Method of Using DNP to Treat Viral Infections, HIV Disease

[0125]History: A 38 year old white male, past intravenous heroin addict, was diagnosed approximately 8 years ago with HIV by ELISA and positive Western blot for HIV p24 and gp41 antigens after presenting with weight loss and thrush. His history included repeated treatment for candidiasis, pneumocystis carinii, and various subcutaneous abscesses. Past medications included sulfamethoxazole, ketoconazole, fluconazole, zidovudine, didanosine and various other antibiotics. For the past year and a half he has been on highly active antiretroviral therapy (HAART) with various HIV protease inhibitors combined with thymidine, purine or cytosine nucleoside and nonnucleoside inhibitors. He was unable to tolerate nelfinavir because of diarrhea. Ritonavir caused intractable vomiting and abdominal pain. Current medications include indinavir, zidovudine and lamivudine. Review of the most recent viral load (VL) and CD4+ lymphocyte counts show...

example 3

Use of DNP to Treat Bacterial Infections, Lyme Disease

[0133]History: A 33 year old white female with a textbook case of Lyme borreliosis related being bitten by a tick and developing a pathognomonic erythema migrans on her right anterior thigh. The rash resolved within two weeks but 3 months later she developed verbal memory impairment, migratory arthritis of the knees, ankles and tibias. Fibromyalgias, tachycardias and a left sided Bell's palsy ensued. Constitutional symptoms of fatigue, malaise and severe depression caused her to undergo psychiatric care for 1-1 / 2 years before she was definitively diagnosed with chronic Borrelia burgdorferi infection. She was treated with ceftriaxone, 2 g intravenously every 12 hours for 14 days. Four months after apparent improvement she developed photophobia, headaches, pronounced memory loss, depression, dysesthesias and a painful, swollen left knee joint. Repeat ELISA, Western blot and DNA-PCR were all positive for B. burgdorferi. Spinal tap s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and / or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and / or free radicals and / or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims benefit of priority to U.S. provisional patent application Ser. No. 60 / 094,286, filed Jul. 27, 1998, which is hereby incorporated by reference in its entirety.FIELD OF INVENTION[0002]This invention relates to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and / or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. This invention further relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, free radicals and hyperthermia-inducible immunogenic determinants. Such pathogens, infected or transformed cells are inactivated or killed without irreparable injury to non-transformed, uninfected, normal cells. More specifically, this invention relates to the diagnosis and treatment of cancer; t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/045A61K31/00A61K31/06A61K41/00
CPCA61K31/00A61K31/06A61K41/0052A61K45/06A61K38/26A61K31/277A61K2300/00A61P31/00A61P33/00Y02A50/30
Inventor BACHYNSKY, NICHOLASROY, WOODIE
Owner TEXAS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com